- Agile Therapeutics recently reported a mixed Q1 earnings with a slight beat on EPS and a miss on revenue. However, the company's earnings call has reignited my bullish outlook.
- Q1 was Twirla's first quarter on the market and its sales numbers were not very impressive. Consequently, the market has pressured AGRX to a new 52-week low.
- I point out a few bullish highlights from the company's earnings call and will discuss my plans for reloading my AGRX position over the remainder of 2021.
For further details see:
Agile Therapeutics: Returning To Bullish Outlook After Encouraging Q1 Earnings